ADMA Biologics Q3 total revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%)

ADMA BIOLOGICS, INC.

2024-Q3 EPS reported $0.35 revenue$308,905,000

Revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%); Adj. EBITDA $45.4M (+256%)
FY2024 guidance raised: revenue >$415M (from >$400M), GAAP net income >$120M (from >$105M), Adj. EBITDA >$160M (from >$150M)
FY2025 guidance raised: revenue >$465M, net income >$165M, Adj. EBITDA >$215M
Appointed KPMG as new independent registered public accounting firm, replacing CohnReznick after 17 years
ASCENIV now >50% of revenue; sBLA filing planned for label expansion; pediatric study database lock in Q4 2024

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.